Latest Hepatitis D Stories
-NIH Principal Investigator to Present Abstract and Poster at Conference on Retroviruses and Opportunistic Infections (CROI) PALO ALTO, Calif., Feb.
RnRMarketResearch.com adds "Hepatitis D - Pipeline Review, H2 2014" to its store. This report provides an overview of the Hepatitis D's therapeutic pipeline. DALLAS, Dec.
PALO ALTO, Calif., Dec.
PALO ALTO, Calif., Dec, 22, 2014 /PRNewswire/ -- Eiger BioPharmaceuticals Incorporated announced the positive results of a Phase 2a study of lonafarnib in patients with chronic hepatitis delta
PALO ALTO, Calif., Dec. 22, 2014 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. today announced that lonafarnib has been granted Orphan Designation by the U.S.
MOSCOW, October 21, 2014 /PRNewswire/ -- Hepatera Ltd and its development partner MYR GmbH announced today the results of clinical trials investigating Myrcludex B in patients
Hepatitis C is a contagious liver disease which results from infection with the Hepatitis C virus (HCV), which is spread primarily through contact with the blood of an infected person.
In its May 2014 survey, polyDNA found that 36% of respondents wanted to know what complications can arise from a hepatitis B infection.
Mortality from viral hepatitis is significantly higher than from HIV/AIDS across EU countries, according to results from The Global Burden of Disease Study 2010 (GBD 2010) which was announced for the first time today at the International Liver CongressTM 2014.
MOSCOW, April 2, 2014 /PRNewswire/ -- Hepatera Ltd.
- The deadly nightshade, Atropa Belladonna, which possesses stupefying or poisonous properties.
- A sleeping-potion; a soporific.
- To mutter deliriously.